SCHEMBL30786303

SCHEMBL30786303

O=C(O)c1ccccc1-c1nn[nH]n1

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
PBRM1 Q86U86 1/20 0.54
IDO1 P14902 1/20 0.54
GAA P10253 1/20 0.54
LDHA P00338 1/20 0.54
AGTR1 P30556 6/20 0.52
AGTR2 P50052 6/20 0.52
FTO Q9C0B1 1/20 0.51
XDH P47989 2/20 0.49
HPGDS O60760 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7019052 1.00 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL30675982 0.85 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL2653334 0.85 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL19283593 0.82 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL11817017 0.81 ALDH1A1 (0.57) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL30610302 0.80 XDH (0.53) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL28492133 0.80 XDH (0.54) ALDH1A1MEN1KMT2AL3MBTL1PBRM1
SCHEMBL7350821 0.79 MEN1 (0.62) ALDH1A1MEN1KMT2AL3MBTL1AGTR1
SCHEMBL24344787 0.78 XDH (0.51) ALDH1A1MEN1KMT2AL3MBTL1IDO1
SCHEMBL31419367 0.76 ALDH1A1 (0.53) ALDH1A1MEN1KMT2AL3MBTL1PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-11-20 US claimed
EP-4538261-A1 N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (CN) 2025-04-16 EP claimed
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF HANGZHOU YIRUI PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) 2025-11-20 US disclosed
EP-4538261-A1 N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF Hangzhou Yirui Pharmaceutical Technology Co., Ltd. (CN) 2025-04-16 EP disclosed
WO-2023237015-A1 N-TETRAZOLYL ARYL UREA DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF 杭州壹瑞医药科技有限公司 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353835-A1 N-TETRAZOLYL ARYL UREA-BASED DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF BDKRB1, BDKRB2, UTS2R ALDH1A1 2190/4885MEN1 1907/4885KMT2A 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.